San Francisco Bay Area biotech stories.
Wednesday, June 29, 2011
Reaction to FDA's Avastin decision
Here's some of the reaction from Wednesday's Food and Drug Administration advisory panel recommendation to revoke approval of Avastin, developed by South San Francisco's Genentech, for women with metastatic breast cancer.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)